Role of PADI4 in Crohn's disease: the citrullination of proteins in the transition from inflammation to fibrosis

Gabriele Dragoni © Gabriele Dragoni

Aim of research

Citrullination is a post-translational modification of proteins, mediated by enzymes called PADs (peptidylarginine deiminases). PAD4 has recently been shown to citrullinate histone 3 (H3cit) in the nucleus, leading to the expulsion of extracellular traps from neutrophils (NETs), whose presence in Crohn’s Disease (CD) is debated.

The aim of this project is to investigate the role of PAD4 in inflammatory and fibrotic contexts of ileal CD.

Understanding the mechanisms of anti-TNF treatment failure in patients with Crohn’s Disease: a proteomic analysis of the PANTS cohort

Neil Chanchlani © Neil Chanchlani

Aim of research

In the Personalised Anti-TNF Therapy in Crohn’s Disease (PANTS) prospective cohort study, we followed 1,610 patients with Crohn’s Disease treated with infliximab or adalimumab for three years. About one in four patients experienced primary non-response and one-third of initial responders lost response, leaving only one-third in remission at one year.  

A limited number of proteomic markers have been implicated in anti-TNF treatment failure, but their relative effects and interactions have not been fully explored. We aim:

1. To identify novel protein biomarkers linked to intestinal inflammation and immunity that influence pharmacokinetic or pharmacodynamic related primary non-response and non-remission at one year, using two multiplex Olink proteomic panels.
2. Validate previously postulated protein markers associated with anti-TNF primary non-response and non-remission at one year, including TREM-1, oncostatin M, Vitamin D, ASCA, ANCA and anti-OmpC.

CCR6 blockade as novel therapeutic strategy against inflammatory bowel disease

Simona Bertoni © Simona Bertoni

Aim of research

CCL20 and its cognate receptor CCR6 are dysregulated in the colonic mucosa and serum of IBD patients; their genes have been identified as susceptibility genes for IBD and an anti-CCL20 neutralizing antibody has been reported to be beneficial in TNBS-induced colitis.
Our working hypothesis is that blocking the CCL20-CCR6 axis represents a novel and promising approach to IBD therapy by limiting neutrophil recruitment to the inflamed tissues and by restoring the balance of effector/regulatory T cells.
Accordingly, our aim is the preclinical validation of small-molecule CCR6 antagonists as potential drug candidates for the treatment of IBD.

Unraveling the immunoregulatory effects of local mesenchymal stromal cell therapy in patients with IBD

Marieke Barnhoorn © Marieke Barnhoorn

Aim of research

Local mesenchymal stromal cell (MSC) therapy is approved for the treatment of Crohn’s Disease-associated perianal fistulas. However, little is known about the mechanism(s) of action of local MSC therapy. In this project we intend to unravel the engraftment and immunoregulatory effects of local MSC therapy in patients with refractory IBD.

The educational programme of the 16^th Congress of ECCO is scheduled prior to the official start of the ECCO Congress and courses take place from July 7-9, 2021. These activities target ECCO’s different interest groups including young gastroenterologists, surgeons, paediatricians, pathologists, IBD Nurses, dietitians, allied health professionals and scientists.

An overview of these activities can be found below. Please note that courses/workshops may run concurrently. As these educational activities have a limited capacity, we encourage you to register at your earliest convenience.

We look forward to seeing you in Copenhagen!

Nuha Yassin  © Nuha Yassin

Ignacio Catalán-Serra © Ignacio Catalán-Serra

Dear IBD colleagues and friends,

Warm greetings from the ECCO News Team as we head towards the end of this challenging year.

Although the COVID-19 pandemic has affected everyone in one way or another, we at ECCO have been adapting to the new circumstances.  The ECCO Team has been working hard to continue to provide not only the best standards of care for IBD patients but also high-quality research, education and training opportunities.

ECCO has taken up the challenge of organising yet another top quality meeting, which on this occasion will be held a little later than our usual conference dates. We would like to invite you to the 16^th Congress of ECCO in Copenhagen in July of 2021, during the beautiful Danish summer!

Laurent Peyrin-Biroulet © ECCO

Dear Friends,

I was hoping that the COVID pandemic would be over by the time I came to write this editorial. Unfortunately, this is not the case. The second wave has started, but there is some good news: we have the first vaccines. This means that we should all be able to meet in Copenhagen in July! I am predicting a big celebration there.

Paul Rutgeerts

Dear Friends and Colleagues!

It is with great sadness that we have to announce the passing of em. Prof. Dr. Paul Rutgeerts on September 12, 2020.

Paul Rutgeerts (°1948, Brussels) obtained his medical degree in 1973 at the KU Leuven and specialised in internal medicine at UZ Leuven. He became a member of the medical staff in gastroenterology in 1978. In 1981 he graduated in higher education with a dissertation on ‘Bile acid disorders in Crohn’s disease’. He started lecturing at the KU Leuven in 1981 and became a full professor in 1990.

Virginie Cluzeau © Virginie Cluzeau

France

N-ECCO National Representative:
Virginie Cluzeau
Job Title: 
Clinical research and patient education IBD Nurse

What influenced your decision to apply for the role of N-ECCO National Representative for your country?

The nurse that I replaced as French representative 4 years ago explained what the position involved. I was really interested to know how it works for nurses in other countries, and I thought that taking up this role could be useful in improving the position of IBD Nurses in France.

Ignacio Catalán-Serra © ECCO

Fernando Magro is Consultant in Gastroenterology and Director of Pharmacology at the University Hospital São João Porto, Portugal. In addition Fernando is also Associate Editor of the UEG Journal and founder of the Portuguese IBD Group. As he started his term as new Education Officer at ECCO'20 we wanted to provide the ECCO News readers with an exclusive interview with him.

Once more, the interview was recorded and can be listened to by clicking on the button below. We hope you will enjoy the introduction to ECCO's Education Officer.

Ignacio Catalán-Serra, ECCO News Associate Editor